Impaired Neutralisation of SARS-CoV-2 Delta Variant in Vaccinated Patients With B Cell Chronic Lymphocytic Leukaemia
Autor: | Farooq Wandroo, Salim Shafeek, Nicola S Logan, Sophie Lee, Shankara Paneesha, Ashley Otter, Sian E Faustini, Dawn Brant, Graham McIlroy, Chris Davis, Tina McSkeane, Guy Pratt, Hayley Rolfe, Rachel Bruton, Christine Stephens, Myah Ali, Paul Moss, Sarah Damery, Jianmin Zuo, Manjit Kaur, Brian J. Willett, Alex G. Richter, Grace Tyson, Helen Parry |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male Cancer Research History COVID-19 Vaccines Polymers and Plastics medicine.drug_class medicine.medical_treatment Antibiotics medicine.disease_cause Industrial and Manufacturing Engineering Immune system Immunity Humans Leukaemia Medicine Diseases of the blood and blood-forming organs Business and International Management Seroconversion Molecular Biology Antibody RC254-282 Aged COVID Coronavirus Aged 80 and over SARS-CoV-2 business.industry Research Vaccination COVID-19 Neoplasms. Tumors. Oncology. Including cancer and carcinogens Hematology Immunotherapy Middle Aged Antibodies Neutralizing Leukemia Lymphocytic Chronic B-Cell HEK293 Cells Oncology Antibody Formation Cohort Immunology Female RC633-647.5 business CLL |
Zdroj: | Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-12 (2022) Journal of Hematology & Oncology |
ISSN: | 1556-5068 1756-8722 |
Popis: | Background Immune suppression is a clinical feature of chronic lymphocytic leukaemia (CLL), and patients show increased vulnerability to SARS-CoV-2 infection and suboptimal antibody responses. Method We studied antibody responses in 500 patients following dual COVID-19 vaccination to assess the magnitude, correlates of response, stability and functional activity of the spike-specific antibody response with two different vaccine platforms. Results Spike-specific seroconversion post-vaccine was seen in 67% of patients compared to 100% of age-matched controls. Amongst responders, titres were 3.7 times lower than the control group. Antibody responses showed a 33% fall over the next 4 months. The use of an mRNA (n = 204) or adenovirus-based (n = 296) vaccine platform did not impact on antibody response. Male gender, BTKi therapy, prophylactic antibiotics use and low serum IgA/IgM were predictive of failure to respond. Antibody responses after CD20-targeted immunotherapy recovered 12 months post treatment. Post-vaccine sera from CLL patients with Spike-specific antibody response showed markedly reduced neutralisation of the SARS-CoV-2 delta variant compared to healthy controls. Patients with previous natural SARS-CoV-2 infection showed equivalent antibody levels and function as healthy donors after vaccination. Conclusions These findings demonstrate impaired antibody responses following dual COVID-19 vaccination in patients with CLL and further define patient risk groups. Furthermore, humoural protection against the globally dominant delta variant is markedly impaired in CLL patients and indicates the need for further optimisation of immune protection in this patient cohort. |
Databáze: | OpenAIRE |
Externí odkaz: |